Similarly, women with HER2-positive cancer infrequently had bone as the first metastatic site compared with those whose cancer was HER2-negative (29 (43.9%) of 66 vs. 98 (58.3%) of 168, respectively, P = 0.047). The gene discussed is ERBB2; the disease is cancer.